TESOFENSINE FOR REDUCTION OF BODY WEIGHT IN PRADER-WILLI PATIENTS

摘要

The present invention relates to a method of reducing body weight or hyperphagia in Prader-Willi patients comprising administering the active compound Tesofensine or a pharmaceutically acceptable salt thereof, preferably by the administration of a controlled release formulation comprising the active compounds tesofensine and a beta blocker. The invention further relates to pharmaceutical compositions comprising no more than 0.150 mg of Tesofensine, or a pharmaceutically acceptable salt thereof, and no more than 25 mg Metoprolol